#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	11510	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2092	538.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1413	1413	C	667	C	641	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	11510	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2092	538.3	0	HET	.	.	.	C207T,G	.	207	207	C	436	436	C	676	C,T,G	526,118,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	11510	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2092	538.3	0	HET	.	.	.	C451T	.	451	451	C	680	680	C	616	C,T	293,310	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21220	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3583	583.4	0	.	n	.	0	T695C	SNP	695	695	T	1117	1117	C	618	C	595	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21220	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3583	583.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2393	2393	C	639	C,T	615,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21220	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3583	583.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2467	2467	A	636	A	617	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21220	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3583	583.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3019	3019	C	625	C	603	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21220	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3583	583.4	0	HET	.	.	.	A1638G	.	1638	1638	A	2060	2060	A	633	A,G	356,260	.	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1286	folP	855	855	100.0	folP.l6.c4.ctg.1	1498	84.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1011	1013	AGC	116;116;116	A,C;G;C	110,1;114;110	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3518	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3316	104.6	1	SNP	p	S91F	1	.	.	271	273	TTC	570	572	TTC	127;124;126	T;T;C	125;123;121	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3518	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3316	104.6	1	SNP	p	G95N	0	.	.	283	285	GGC	582	584	GGC	127;128;127	G;G;C	119;123;122	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3518	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3316	104.6	1	SNP	p	D95G	1	.	.	283	285	GGC	582	584	GGC	127;128;127	G;G;C	119;123;122	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1182	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1610	72.5	1	SNP	p	G45D	0	.	.	133	135	GGC	619	621	GGC	139;137;135	G;G;C,G	137;133;131,1	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	656	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1015	63.9	0	.	n	.	0	A197.	DEL	197	197	A	646	646	A	144	A	136	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2936	133.1	1	SNP	p	D86N	0	.	.	256	258	GAC	622	624	GAC	163;164;164	G;A;C	158;153;160	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2936	133.1	1	SNP	p	R87W	0	.	.	259	261	CGT	625	627	CGT	165;167;165	C,A;G;T,G	159,1;162;156,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2936	133.1	1	SNP	p	R87I	0	.	.	259	261	CGT	625	627	CGT	165;167;165	C,A;G;T,G	159,1;162;156,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2936	133.1	1	SNP	p	S87R	1	.	.	259	261	CGT	625	627	CGT	165;167;165	C,A;G;T,G	159,1;162;156,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2936	133.1	1	SNP	p	S88P	0	.	.	262	264	TCC	628	630	TCC	164;166;165	T;C;C	159;158;158	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2800	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2619	105.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1498	1500	GGC	135;131;129	G;G;C	132;127;125	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1385	1387	GCC	174;176;176	G;C;C	168;171;171	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1388	1390	ATG	175;174;175	A;T;GAA,GA	170;168;168,1	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1400	1402	ACC	179;180;180	A;C;C	174;176;176	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1400	1402	ACC	179;180;180	A;C;C	174;176;176	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1901	1903	ACC	155;154;154	A;C;C	147;148;150	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1955	1957	GCG	138;138;139	G;C;G	134;133;135	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1955	1957	GCG	138;138;139	G;C;G	134;133;135	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2078	2080	GGT	111;109;109	G;G;T	108;107;106	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2087	2089	AGC	105;104;106	A;G;C	99;101;101	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2800	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2662	103.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2105	2107	CCG	85;86;84	C,G;C,G;G	73,3;76,2;74	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4354	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3143	136.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1646	1648	CCG	146;148;149	C;C;G,A	139;145;142,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1844	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1912	94.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	587	587	C	118	C	113	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	A251V	NONSYN	751	753	GCG	71	73	GTA	25;25;25	G;T;A	23;22;23	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	S271T	NONSYN	811	813	TCG	131	133	ACT	49;47;44	A;C;T	47;45;41	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	137	139	GAT	38;37;36	G;A;T	38;35;36	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	D276N	NONSYN	826	828	GAT	146	148	AAC	36;36;36	A;A;C	36;36;36	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	N277H	NONSYN	829	831	AAC	149	151	CAC	36;36;37	C;A;C	36;35;37	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	R307E	NONSYN	919	921	AGA	239	241	GAA	11;11;11	G;A;A	11;11;11	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	T311A	NONSYN	931	933	ACA	251	253	GCA	12;12;12	G;C;A	12;12;12	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	E312D	NONSYN	934	936	GAA	254	256	GAC	12;12;12	G;A;C	12;12;12	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	F314I	NONSYN	940	942	TTC	260	262	ATC	13;13;13	A;T;C	13;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	A316S	NONSYN	946	948	GCG	266	268	TCG	13;13;13	T;C;G	13;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	V318A	NONSYN	952	954	GTC	272	274	GCC	13;13;13	G;C;C	13;13;12	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	G319S	NONSYN	955	957	GGC	275	277	AGC	13;13;13	A;G;C	13;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	G320A	NONSYN	958	960	GGT	278	280	GCC	13;12;12	G;C;C	13;12;11	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	236	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	444	20.3	0	.	p	.	0	G322V	NONSYN	964	966	GGT	284	286	GTT	12;12;12	G;T;T	12;12;12	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2238	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1620	136.3	1	SNP	p	G120K	1	.	.	358	360	AAG	683	685	AAG	184;185;184	A;A;G,A	175;179;175,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2238	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1620	136.3	1	SNP	p	A121N	1	.	.	361	363	AAC	686	688	AAC	183;182;181	A;A;C	177;178;173	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2238	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1620	136.3	1	SNP	p	N121D	0	.	.	361	363	AAC	686	688	AAC	183;182;181	A;A;C	177;178;173	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8230	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4842	167.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	930	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1151	79.2	1	SNP	p	V57M	1	.	.	169	171	ATG	574	576	ATG	171;172;177	A;T;G,A	165;168;169,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
